Other tumor biomarkers are today commonly evaluated, including CD20, Ki-67, as well as MYC, BCL2, and BCL6, since a worst prognosis is predicted by the co-occurrence of MYC rearrangements with BCL2 and/or BCL6 rearrangements (i.e., “double-hit” and “triple-hit” lymphoma, respectively)[9,10]. The gene discussed is MYC; the disease is lymphoma.